Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus and the associated desensitisation of insulin signalling has been identified as a risk factor for progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease and others. Glucagon‐like peptide 1 (GLP‐1) is a hormone that has growth factor‐like and neuroprotective properties. Several clinical trials have been conducted, testing GLP‐1 receptor agonists in patients with Alzheimer's disease, Parkinson's disease or diabetes‐induced memory impairments. The trials showed clear improvements in Alzheimer's disease, Parkinson's disease and diabetic patients. Glucose‐dependent insulinotropic polypeptide/gastric inhibitory peptide (GIP) is the ‘sister’ incretin hormone of GLP‐1. GIP analogues have shown neuroprotective effects in animal models of disease and can improve on the effects of GLP‐1. Novel dual GLP‐1/GIP receptor agonists have been developed that can enter the brain at an enhanced rate. The improved neuroprotective effects of these drugs suggest that they are superior to single GLP‐1 receptor agonists and could provide disease‐modifying care for Alzheimer's disease and Parkinson's disease patients. LINKED ARTICLES: This article is part of a themed issue on GLP1 receptor ligands (BJP 75th Anniversary). To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.4/issuetoc
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“cardiovascular causes in the liraglutide group (Marso et al., 2016).”
BackgroundInflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“It plays important physiological signalling roles to control cell metabolism and energy utilisation (Baggio & Drucker, 2007).”
BackgroundNeuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 3×
“…observation, impaired insulin signalling in the brains of people with Alzheimer's disease or Parkinson's disease had been identified (Athauda & Foltynie, 2016; Cheong et al., 2020; Craft, 2005; Freiherr et al., 2013; Hölscher, 2011; Moroo et al., 1994; Steen et al., 2005; Talbot et al., 2012).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Another very popular and effec- tive drug class is the glucagon-like peptide 1 (GLP-1) receptor agonist group that currently has several different drugs on the market for the treatment of type 2 diabetes mellitus (Dhillon, 2018; Müller et al., 2019; Schmidt et al., 2014).”
BackgroundSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 3×
“…observation, impaired insulin signalling in the brains of people with Alzheimer's disease or Parkinson's disease had been identified (Athauda & Foltynie, 2016; Cheong et al., 2020; Craft, 2005; Freiherr et al., 2013; Hölscher, 2011; Moroo et al., 1994; Steen et al., 2005; Talbot et al., 2012).”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 4×
“Unfortunately, there are few studies that measure levels of such drugs in the CSF in humans to estimate the BBB penetrations.”
BackgroundMethodInfluential
Research works printed but not linked: 145
- 10.1007/s00210-018-1497-1 · DOI
- 10.1038/nrn812 · DOI · Paper page
- 10.1016/S1474-4422(02)00133-3 · DOI · Paper page
- 10.1177/1533317519899546 · DOI · Paper page
- 10.1016/j.amjms.2017.05.002 · DOI
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors, British Journal of Pharmacology, 176, S21
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors, British Journal of Pharmacology, 176, S247
- Alexander S. P. H., 2019, THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels, British Journal of Pharmacology, 176, S142
- 10.1016/j.jalz.2017.09.011 · DOI · Paper page
- 10.1007/s00702-009-0272-3 · DOI
- 10.1016/j.pneurobio.2016.10.001 · DOI · Paper page
- 10.1001/jamaneurol.2018.4304 · DOI · Paper page
- 10.3233/JPD-140364 · DOI · Paper page
- 10.1016/j.freeradbiomed.2004.04.007 · DOI
- 10.3390/ijms18112493 · DOI · Paper page
- 10.1007/s11011-017-0059-4 · DOI
- 10.1002/path.5056 · DOI · Paper page
- 10.1073/pnas.0901402106 · DOI · Paper page
- 10.3233/JAD-180808 · DOI · Paper page
- 10.1016/j.neuroscience.2014.02.022 · DOI
- 10.4239/wjd.v6.i6.807 · DOI · Paper page
- 10.1097/WNR.0000000000000548 · DOI · Paper page
- 10.1016/j.ejphar.2018.03.024 · DOI
- 10.1007/s11064-017-2250-8 · DOI
- 10.3233/JPD-191900 · DOI · Paper page
- 10.1054/npep.1999.0757 · DOI
- 10.1038/ijo.2015.136 · DOI
- 10.1016/j.brainresbull.2019.08.001 · DOI
- 10.1124/pr.112.005850 · DOI
- 10.1186/1742-2094-11-51 · DOI · Paper page
- 10.1111/bph.14471 · DOI
- 10.3233/JAD-141791 · DOI · Paper page
- 10.1196/annals.1332.005 · DOI · Paper page
- 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- 10.1111/j.1464-5491.2008.02484.x · DOI · Paper page
- 10.1016/j.neurobiolaging.2005.08.021 · DOI · Paper page
- 10.1001/archneurol.2011.233 · DOI · Paper page
- Dailey G. E., 2007, Using prandial insulin to achieve glycemic control in type 2 diabetes, The Journal of Family Practice, 56, 735
- 10.1016/j.neuropharm.2017.08.022 · DOI · Paper page
- 10.1042/CS20110374 · DOI · Paper page
- 10.2337/db12-0988 · DOI · Paper page
- 10.3389/fneur.2018.00292 · DOI · Paper page
- 10.1016/j.biopha.2018.10.066 · DOI · Paper page
- 10.1016/S0531-5565(00)00149-2 · DOI
- 10.1016/j.pharmthera.2006.11.007 · DOI · Paper page
- 10.1016/j.neuroscience.2012.10.045 · DOI
- Edison P. Femminella G. Frangou E. Love S. Busza G. Holmes C. Ritchie C. Lawrence R. McFarlane B. Tadros G. Ridha B. H. &Bannister C.(2020).Evaluating the effects of the novel GLP‐1 analogue liraglutide in Alzheimer's disease (ELAD study). CTAD conference 2020 abstract OC30.
- Egefjord L., 2012, Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease ‐ protocol for a controlled, randomized double‐blinded trial, Danish Medical Journal, 59, A4519
- 10.1159/000118039 · DOI · Paper page
- 10.1080/02699052.2019.1587000 · DOI · Paper page
- 10.3233/JAD-121888 · DOI · Paper page
- 10.1186/alzrt174 · DOI · Paper page
- 10.1186/s13063-019-3259-x · DOI · Paper page
- 10.1016/j.neuropharm.2018.02.012 · DOI
- 10.4061/2011/436813 · DOI · Paper page
- 10.1097/FBP.0b013e32833c8544 · DOI
- 10.1177/1479164118788079 · DOI · Paper page
- 10.1007/s40263-013-0076-8 · DOI · Paper page
- 10.1111/j.1749-6632.1999.tb07839.x · DOI · Paper page
- 10.1007/s12035-013-8404-z · DOI
- 10.1007/s12035-012-8339-9 · DOI · Paper page
- 10.1002/cne.24905 · DOI · Paper page
- 10.1186/1742-2094-5-3 · DOI · Paper page
- 10.1111/jdi.12420 · DOI · Paper page
- 10.1002/jnr.22565 · DOI · Paper page
- 10.1097/WNR.0000000000000490 · DOI · Paper page
- 10.1016/j.brainres.2015.12.052 · DOI
- 10.1371/journal.pone.0158205 · DOI · Paper page
- 10.3233/JAD-143090 · DOI · Paper page
- 10.1186/1742-2094-5-19 · DOI · Paper page
- 10.1042/BST0390891 · DOI · Paper page
- 10.1042/BST20140016 · DOI · Paper page
- 10.1016/j.neuropharm.2018.01.040 · DOI · Paper page
- 10.3389/fnagi.2019.00088 · DOI · Paper page
- Hölscher C., 2020, International review of neurobiology: Metabolic drivers and bioenergetic components of neurodegenerative disease, 65
- 10.1016/j.neuropharm.2018.11.002 · DOI · Paper page
- 10.1007/978-3-7091-7508-8_18 · DOI · Paper page
- 10.1016/j.ejphar.2004.02.049 · DOI · Paper page
- 10.1007/BF00314304 · DOI · Paper page
- 10.1016/j.neuropharm.2017.02.013 · DOI
- 10.1111/jnc.13736 · DOI · Paper page
- 10.1515/revneuro-2015-0021 · DOI · Paper page
- 10.1016/j.brainres.2015.09.035 · DOI
- 10.1002/ddr.21297 · DOI
- 10.1016/0196-9781(94)90016-7 · DOI
- 10.1016/j.neuropharm.2018.02.027 · DOI
- 10.1016/j.neuropharm.2017.11.015 · DOI · Paper page
- 10.1007/s11064-016-1890-4 · DOI
- 10.1007/s11010-016-2678-1 · DOI
- 10.1002/jnr.22596 · DOI · Paper page
- 10.3233/JAD-2006-9102 · DOI · Paper page
- Li C., 2020, The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD, Brain and Behavior: A Cognitive Neuroscience Perspective, 10, e01505, 10.1002/brb3.1505 · DOI · Paper page
- 10.1186/s12868-016-0272-9 · DOI · Paper page
- 10.3233/JAD-2010-1314 · DOI · Paper page
- 10.1016/j.neuropharm.2015.10.002 · DOI
- 10.1016/j.ejphar.2016.11.050 · DOI
- 10.1523/JNEUROSCI.5180-14.2015 · DOI · Paper page
- 10.3389/fphar.2020.00136 · DOI
- 10.1007/s12017-012-8199-5 · DOI
- 10.1016/j.cmet.2013.11.002 · DOI · Paper page
- 10.1023/A:1007627725251 · DOI
- 10.1111/j.1463-1326.2011.01357.x · DOI · Paper page
- 10.1177/1533317520953041 · DOI · Paper page
- 10.1016/j.neuropharm.2013.08.005 · DOI · Paper page
- 10.1016/j.bbr.2015.07.024 · DOI
- 10.1002/(SICI)1096‐9861(19990111)403:2<261::AID‐CNE8>3.0.CO;2‐5 · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5
- 10.1016/0361-9230(92)90068-9 · DOI
- 10.1007/BF00313602 · DOI · Paper page
- 10.3233/JAD-180578 · DOI · Paper page
- 10.1371/journal.pone.0214364 · DOI · Paper page
- 10.1002/jnr.21349 · DOI · Paper page
- 10.11648/j.ajbio.20150301.13 · DOI
- 10.3390/ijms22020860 · DOI · Paper page
- 10.3233/JAD-180584 · DOI · Paper page
- 10.1038/s41598-017-16488-x · DOI · Paper page
- 10.1371/journal.pone.0065420 · DOI
- 10.1371/journal.pone.0058784 · DOI · Paper page
- 10.1016/j.ejphar.2012.12.012 · DOI · Paper page
- 10.1016/j.ejphar.2010.10.059 · DOI
- 10.1111/j.1463-1326.2010.01259.x · DOI · Paper page
- 10.1016/j.ejphar.2016.04.052 · DOI
- 10.1016/0166-2236(95)93890-A · DOI · Paper page
- 10.1016/j.neuropharm.2017.11.016 · DOI
- 10.1111/dom.12269 · DOI · Paper page
- 10.3389/fnagi.2019.00302 · DOI · Paper page
- 10.1016/j.bbr.2017.03.032 · DOI
- 10.1002/mds.26734 · DOI
- 10.2217/nmt.13.73 · DOI · Paper page
- Talbot K.(2021).Direct demonstration of brain insulin resistance in Alzheimer's and Parkinson's disease dementia and its alleviation with incretin receptor agonists. AD/PD 2021 conference Boston USA
- 10.1038/jcbfm.2011.51 · DOI · Paper page
- 10.1210/endo.133.6.8243312 · DOI · Paper page
- 10.1080/14728222.2018.1487952 · DOI · Paper page
- 10.1016/j.ejphar.2017.03.059 · DOI
- 10.1016/j.eplepsyres.2018.03.009 · DOI
- 10.1016/j.bbr.2018.08.006 · DOI · Paper page
- 10.1523/ENEURO.0053-14.2015 · DOI · Paper page
- 10.3390/ijms20051050 · DOI · Paper page
- 10.3390/ijms19041153 · DOI
- 10.1016/j.ejphar.2017.06.029 · DOI
- 10.1016/j.npep.2018.07.003 · DOI · Paper page
- 10.3233/JPD-191768 · DOI · Paper page
- 10.1016/j.bbr.2015.07.021 · DOI
- 10.1016/j.peptides.2019.170184 · DOI · Paper page
- 10.1016/j.bbrc.2019.01.103 · DOI · Paper page
- 10.1038/srep26859 · DOI · Paper page
Cited by
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationTrapp, S., & Brierley, D. I. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15638 · Cited by 154
“Although this topic is reviewed in detail by another article within this themed issue (Hölscher, 2021), we would like to briefly consider the following points.”
BackgroundAnti-Inflammatory Effects of GLP-1 Receptor Activation in the Brain in Neurodegenerative Diseases
Diz-Chaves, Y., Mastoor, Z., Spuch, C., González-Matías, L. C., & Mallo, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179583 · Cited by 148
“to trigger an inflammatory response in the brain to increase its density, which indicates that it plays a role in controlling inflammation [22,91].”
BackgroundWang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
Self-citationTargeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
Meurot, C., Jacques, C., Martin, C., Sudre, L., Breton, J., Rattenbach, R., Bismuth, K., & Berenbaum, F. (2022) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2022.02.001 · Cited by 94
Metadata
- Authors
- Hölscher, C.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2021-05-29
- Volume
- 179
- Issue
- 4
- Pages
- 695-714
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W3159277791
- Cited by
- 145
- References
- 58
- FWCI
- 11.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders. https://app.cochat.ai/papers/10.1111/bph.15508
- The paper
- Hölscher, C. (2022). Protective properties of GLP‐1 and associated peptide hormones in neurodegenerative disorders. British Journal of Pharmacology. https://doi.org/10.1111/bph.15508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.